Mydecine Innovations Group Stock Current Liabilities
| MYCOF Stock | USD 0 0 44.00% |
Mydecine Innovations Group fundamentals help investors to digest information that contributes to Mydecine Innovations' financial success or failures. It also enables traders to predict the movement of Mydecine Pink Sheet. The fundamental analysis module provides a way to measure Mydecine Innovations' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mydecine Innovations pink sheet.
Mydecine |
Mydecine Innovations Group Company Current Liabilities Analysis
Mydecine Innovations' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Mydecine Innovations Group has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Mydecine Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mydecine Innovations' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mydecine Innovations could also be used in its relative valuation, which is a method of valuing Mydecine Innovations by comparing valuation metrics of similar companies.Mydecine Innovations is currently under evaluation in current liabilities category among its peers.
Mydecine Fundamentals
| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 | |||
| Current Valuation | 8.64 M | |||
| Shares Outstanding | 13.01 M | |||
| Shares Owned By Insiders | 8.71 % | |||
| Price To Book | 23.41 X | |||
| Price To Sales | 677.59 X | |||
| Revenue | 7.49 K | |||
| Gross Profit | 7.49 K | |||
| EBITDA | (23.14 M) | |||
| Net Income | (28.9 M) | |||
| Cash And Equivalents | 324.15 K | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 1.26 X | |||
| Book Value Per Share | (0.36) X | |||
| Cash Flow From Operations | (24.05 M) | |||
| Earnings Per Share | (4.68) X | |||
| Target Price | 140.0 | |||
| Number Of Employees | 11 | |||
| Beta | 3.42 | |||
| Market Capitalization | 5.94 M | |||
| Total Asset | 7.58 M | |||
| Z Score | -9.3 | |||
| Net Asset | 7.58 M |
About Mydecine Innovations Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mydecine Innovations Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mydecine Innovations using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mydecine Innovations Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.